Telehealth

Canadian digital pharmacy TelyRx now trades on OTCQX, a strategic move to access U.S. capital and scale its cash-pay model in a booming market.

In a move signaling a new era for Chinese healthcare, Fangzhou and Tencent are combining specialized AI with massive tech scale. Is this the blueprint for market dominance?

A new class of doctor is bridging the gap between lab and patient. Meet the physician-scientists tackling deadly diseases with revolutionary new approaches.

NaphCare defends its Alabama prison healthcare contract, touting awards and stability. But can its playbook build lasting value in a deeply troubled system?

A pharma revolution is brewing for Generalized Anxiety Disorder. As prevalence soars, novel therapies targeting new neural pathways promise to upend the market.

Beyond the $1M prize, the Hult Prize is an engine for durable value, creating a new class of resilient, purpose-driven ventures investors can't ignore.

Eli Lilly's partnership with cash-pay platform Sesame is more than a deal; it's a blueprint for a decentralized, direct-to-consumer healthcare market.

A new study reveals treating advanced gum disease has up to 10x the environmental impact of prevention, reframing sustainability from recycling to daily habits.

As AI sweeps through medicine, Gigi Yuen-Reed's recognition highlights a crucial strategy: building systems that empower, not replace, human expertise.

GoHealth's third straight Georgia Fast 40 win isn't just an award; it's a signal. We dissect the 'connected care' model driving its explosive growth.

As Insulet unveils pivotal data, a deeper look reveals a strategy to not just improve tech, but to fundamentally change the daily reality of diabetes.

A new partnership with Scala.AI aims to move beyond simple telehealth, using deep operational intelligence to fix healthcare's costly fragmentation and poor navigation.

Marking 10 years, Wellpoint Iowa's $5M+ investment in community programs reveals a strategic playbook for tackling the social drivers of health.

The market for T-cell malignancy treatments is set to surpass $1.8B, fueled by a pipeline of innovative drugs aiming to meet vast unmet patient needs.

With a severe shortage of addiction specialists, one treatment provider is launching a university. Is this the model to scale expertise and finally turn the tide?

Swiss brand NIANCE is moving beyond creams to build a global ecosystem of longevity clinics. It's a high-stakes bet on science in a trillion-dollar market.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

A new report from Garmin offers more than just stats on running and cycling. It's a window into our collective habits, motivations, and the powerful feedback loop between technology and human behavior.

A new partnership aims to slash clinician onboarding times using AI, tackling a 7.2M patient backlog. But can technology solve a deeply human workforce crisis?

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?